nodes	percent_of_prediction	percent_of_DWPC	metapath
Sildenafil—CYP1A1—Clobetasol propionate—psoriasis	0.0882	0.126	CbGbCtD
Sildenafil—ABCC10—Cyclosporine—psoriasis	0.0845	0.121	CbGbCtD
Sildenafil—CYP1A1—Methoxsalen—psoriasis	0.0463	0.0663	CbGbCtD
Sildenafil—ABCC10—Methotrexate—psoriasis	0.0447	0.0641	CbGbCtD
Sildenafil—CYP3A5—Beclomethasone—psoriasis	0.0401	0.0574	CbGbCtD
Sildenafil—CYP1A1—Cholecalciferol—psoriasis	0.0307	0.0439	CbGbCtD
Sildenafil—ABCC4—Methotrexate—psoriasis	0.0215	0.0308	CbGbCtD
Sildenafil—CYP2D6—Hydroxyurea—psoriasis	0.0186	0.0267	CbGbCtD
Sildenafil—CYP3A7—Hydrocortisone—psoriasis	0.0171	0.0245	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0171	0.0245	CbGbCtD
Sildenafil—CYP3A7—Cyclosporine—psoriasis	0.0161	0.0231	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0161	0.0231	CbGbCtD
Sildenafil—CYP3A5—Mycophenolate mofetil—psoriasis	0.016	0.0229	CbGbCtD
Sildenafil—CYP2C19—Cholecalciferol—psoriasis	0.0149	0.0213	CbGbCtD
Sildenafil—CYP3A4—Calcitriol—psoriasis	0.0139	0.02	CbGbCtD
Sildenafil—CYP1A1—Dexamethasone—psoriasis	0.0133	0.019	CbGbCtD
Sildenafil—CYP3A5—Hydrocortisone—psoriasis	0.0128	0.0183	CbGbCtD
Sildenafil—CYP2C9—Cholecalciferol—psoriasis	0.0123	0.0177	CbGbCtD
Sildenafil—CYP3A5—Cyclosporine—psoriasis	0.0121	0.0173	CbGbCtD
Sildenafil—CYP2D6—Cholecalciferol—psoriasis	0.0113	0.0162	CbGbCtD
Sildenafil—CYP3A4—Methoxsalen—psoriasis	0.0108	0.0155	CbGbCtD
Sildenafil—CYP3A7—Dexamethasone—psoriasis	0.0106	0.0152	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0106	0.0152	CbGbCtD
Sildenafil—CYP2C19—Prednisone—psoriasis	0.0103	0.0147	CbGbCtD
Sildenafil—CYP2E1—Dexamethasone—psoriasis	0.0103	0.0147	CbGbCtD
Sildenafil—CYP2C19—Cyclosporine—psoriasis	0.00976	0.014	CbGbCtD
Sildenafil—CYP2C9—Cyclosporine—psoriasis	0.00811	0.0116	CbGbCtD
Sildenafil—CYP3A5—Dexamethasone—psoriasis	0.00797	0.0114	CbGbCtD
Sildenafil—CYP2D6—Cyclosporine—psoriasis	0.00742	0.0106	CbGbCtD
Sildenafil—CYP3A4—Cholecalciferol—psoriasis	0.00718	0.0103	CbGbCtD
Sildenafil—CYP2C19—Dexamethasone—psoriasis	0.00643	0.0092	CbGbCtD
Sildenafil—CYP3A4—Mycophenolate mofetil—psoriasis	0.00623	0.00892	CbGbCtD
Sildenafil—CYP3A4—Triamcinolone—psoriasis	0.00623	0.00892	CbGbCtD
Sildenafil—CYP2C9—Dexamethasone—psoriasis	0.00534	0.00765	CbGbCtD
Sildenafil—CYP3A4—Betamethasone—psoriasis	0.00534	0.00765	CbGbCtD
Sildenafil—CYP3A4—Prednisolone—psoriasis	0.00527	0.00755	CbGbCtD
Sildenafil—CYP3A4—Hydrocortisone—psoriasis	0.005	0.00716	CbGbCtD
Sildenafil—CYP3A4—Prednisone—psoriasis	0.00498	0.00713	CbGbCtD
Sildenafil—CYP2D6—Dexamethasone—psoriasis	0.00489	0.007	CbGbCtD
Sildenafil—CYP3A4—Cyclosporine—psoriasis	0.00472	0.00676	CbGbCtD
Sildenafil—CYP3A4—Dexamethasone—psoriasis	0.00311	0.00445	CbGbCtD
Sildenafil—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00137	0.0434	CbGpPWpGaD
Sildenafil—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.00117	0.0371	CbGpPWpGaD
Sildenafil—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00105	0.0335	CbGpPWpGaD
Sildenafil—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00097	0.0308	CbGpPWpGaD
Sildenafil—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000962	0.0305	CbGpPWpGaD
Sildenafil—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000905	0.0287	CbGpPWpGaD
Sildenafil—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.000847	0.0269	CbGpPWpGaD
Sildenafil—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000846	0.0269	CbGpPWpGaD
Sildenafil—CYP1A1—Xenobiotics—CYP2S1—psoriasis	0.000799	0.0254	CbGpPWpGaD
Sildenafil—PDE5A—Nitric oxide stimulates guanylate cyclase—NOS2—psoriasis	0.000788	0.025	CbGpPWpGaD
Sildenafil—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000654	0.0208	CbGpPWpGaD
Sildenafil—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000601	0.0191	CbGpPWpGaD
Sildenafil—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000596	0.0189	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—SERPINB8—psoriasis	0.000577	0.0183	CbGpPWpGaD
Sildenafil—ABCC4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000534	0.017	CbGpPWpGaD
Sildenafil—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000486	0.0154	CbGpPWpGaD
Sildenafil—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000479	0.0152	CbGpPWpGaD
Sildenafil—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000394	0.0125	CbGpPWpGaD
Sildenafil—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000393	0.0125	CbGpPWpGaD
Sildenafil—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000352	0.0112	CbGpPWpGaD
Sildenafil—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000351	0.0112	CbGpPWpGaD
Sildenafil—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000347	0.011	CbGpPWpGaD
Sildenafil—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000347	0.011	CbGpPWpGaD
Sildenafil—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000332	0.0105	CbGpPWpGaD
Sildenafil—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000327	0.0104	CbGpPWpGaD
Sildenafil—PDE5A—Platelet homeostasis—NOS2—psoriasis	0.000307	0.00974	CbGpPWpGaD
Sildenafil—PDE6G—Diseases associated with visual transduction—APOE—psoriasis	0.000289	0.00916	CbGpPWpGaD
Sildenafil—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000285	0.00906	CbGpPWpGaD
Sildenafil—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000285	0.00904	CbGpPWpGaD
Sildenafil—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000271	0.00862	CbGpPWpGaD
Sildenafil—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000269	0.00854	CbGpPWpGaD
Sildenafil—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000268	0.00851	CbGpPWpGaD
Sildenafil—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00025	0.00793	CbGpPWpGaD
Sildenafil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000248	0.00786	CbGpPWpGaD
Sildenafil—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000246	0.00782	CbGpPWpGaD
Sildenafil—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000244	0.00776	CbGpPWpGaD
Sildenafil—ABCC5—NRF2 pathway—TGFA—psoriasis	0.000231	0.00734	CbGpPWpGaD
Sildenafil—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000225	0.00714	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—SERPINB8—psoriasis	0.000222	0.00703	CbGpPWpGaD
Sildenafil—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00022	0.00699	CbGpPWpGaD
Sildenafil—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000209	0.00664	CbGpPWpGaD
Sildenafil—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000206	0.00655	CbGpPWpGaD
Sildenafil—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000202	0.00643	CbGpPWpGaD
Sildenafil—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000201	0.00637	CbGpPWpGaD
Sildenafil—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000173	0.00551	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR ligand binding—HCAR2—psoriasis	0.000171	0.00544	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—ITGAL—psoriasis	0.000168	0.00532	CbGpPWpGaD
Sildenafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000163	0.00518	CbGpPWpGaD
Sildenafil—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000163	0.00516	CbGpPWpGaD
Sildenafil—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000162	0.00513	CbGpPWpGaD
Sildenafil—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000161	0.00512	CbGpPWpGaD
Sildenafil—ABCC4—NRF2 pathway—TGFA—psoriasis	0.00016	0.00509	CbGpPWpGaD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000159	0.00505	CbGpPWpGaD
Sildenafil—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000152	0.00481	CbGpPWpGaD
Sildenafil—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000151	0.0048	CbGpPWpGaD
Sildenafil—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000151	0.0048	CbGpPWpGaD
Sildenafil—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000149	0.00475	CbGpPWpGaD
Sildenafil—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000149	0.00474	CbGpPWpGaD
Sildenafil—ABCC5—Fluoropyrimidine Activity—TP53—psoriasis	0.000148	0.0047	CbGpPWpGaD
Sildenafil—ABCC10—Transmembrane transport of small molecules—CP—psoriasis	0.000148	0.00469	CbGpPWpGaD
Sildenafil—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000143	0.00454	CbGpPWpGaD
Sildenafil—ABCC10—Transmembrane transport of small molecules—CARM1—psoriasis	0.000141	0.00448	CbGpPWpGaD
Sildenafil—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000141	0.00447	CbGpPWpGaD
Sildenafil—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000141	0.00447	CbGpPWpGaD
Sildenafil—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000139	0.0044	CbGpPWpGaD
Sildenafil—ADORA2A—Monoamine Transport—TNF—psoriasis	0.000136	0.00432	CbGpPWpGaD
Sildenafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000132	0.0042	CbGpPWpGaD
Sildenafil—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000131	0.00415	CbGpPWpGaD
Sildenafil—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000131	0.00415	CbGpPWpGaD
Sildenafil—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000123	0.00391	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—HCAR2—psoriasis	0.000122	0.00386	CbGpPWpGaD
Sildenafil—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000117	0.00371	CbGpPWpGaD
Sildenafil—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000117	0.00371	CbGpPWpGaD
Sildenafil—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000115	0.00366	CbGpPWpGaD
Sildenafil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000114	0.00361	CbGpPWpGaD
Sildenafil—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000113	0.0036	CbGpPWpGaD
Sildenafil—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000113	0.00358	CbGpPWpGaD
Sildenafil—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000108	0.00341	CbGpPWpGaD
Sildenafil—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000107	0.00338	CbGpPWpGaD
Sildenafil—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000106	0.00337	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—TAGAP—psoriasis	0.000105	0.00335	CbGpPWpGaD
Sildenafil—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000105	0.00334	CbGpPWpGaD
Sildenafil—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000104	0.00331	CbGpPWpGaD
Sildenafil—ABCC4—Fluoropyrimidine Activity—TP53—psoriasis	0.000103	0.00326	CbGpPWpGaD
Sildenafil—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	9.98e-05	0.00317	CbGpPWpGaD
Sildenafil—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	9.76e-05	0.0031	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—HCAR2—psoriasis	9.67e-05	0.00307	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR ligand binding—CCL20—psoriasis	8.89e-05	0.00282	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—HCAR2—psoriasis	8.78e-05	0.00279	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—NDUFA5—psoriasis	8.35e-05	0.00265	CbGpPWpGaD
Sildenafil—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	8.24e-05	0.00262	CbGpPWpGaD
Sildenafil—CYP1A1—Oxidative Stress—NFKB1—psoriasis	8.02e-05	0.00255	CbGpPWpGaD
Sildenafil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.93e-05	0.00252	CbGpPWpGaD
Sildenafil—ABCC5—Transmembrane transport of small molecules—CP—psoriasis	7.76e-05	0.00246	CbGpPWpGaD
Sildenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.5e-05	0.00238	CbGpPWpGaD
Sildenafil—ABCC5—Transmembrane transport of small molecules—CARM1—psoriasis	7.4e-05	0.00235	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—CYP2S1—psoriasis	7.1e-05	0.00225	CbGpPWpGaD
Sildenafil—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.03e-05	0.00223	CbGpPWpGaD
Sildenafil—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.93e-05	0.0022	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—NOS2—psoriasis	6.87e-05	0.00218	CbGpPWpGaD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.84e-05	0.00217	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—LEP—psoriasis	6.76e-05	0.00215	CbGpPWpGaD
Sildenafil—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.74e-05	0.00214	CbGpPWpGaD
Sildenafil—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	6.73e-05	0.00214	CbGpPWpGaD
Sildenafil—ABCC4—Platelet degranulation—VEGFA—psoriasis	6.69e-05	0.00212	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—ITGAL—psoriasis	6.43e-05	0.00204	CbGpPWpGaD
Sildenafil—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	6.37e-05	0.00202	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—CCL20—psoriasis	6.31e-05	0.00201	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—NOS2—psoriasis	6.3e-05	0.002	CbGpPWpGaD
Sildenafil—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	6.2e-05	0.00197	CbGpPWpGaD
Sildenafil—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.06e-05	0.00193	CbGpPWpGaD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.92e-05	0.00188	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—PPARG—psoriasis	5.89e-05	0.00187	CbGpPWpGaD
Sildenafil—Abdominal pain—Cyclosporine—psoriasis	5.84e-05	0.000216	CcSEcCtD
Sildenafil—Body temperature increased—Cyclosporine—psoriasis	5.84e-05	0.000216	CcSEcCtD
Sildenafil—Anxiety—Dexamethasone—psoriasis	5.83e-05	0.000216	CcSEcCtD
Sildenafil—Anxiety—Betamethasone—psoriasis	5.83e-05	0.000216	CcSEcCtD
Sildenafil—Vomiting—Mycophenolic acid—psoriasis	5.8e-05	0.000215	CcSEcCtD
Sildenafil—Discomfort—Betamethasone—psoriasis	5.78e-05	0.000214	CcSEcCtD
Sildenafil—Discomfort—Dexamethasone—psoriasis	5.78e-05	0.000214	CcSEcCtD
Sildenafil—Dyspepsia—Hydrocortisone—psoriasis	5.78e-05	0.000214	CcSEcCtD
Sildenafil—Haemoglobin—Methotrexate—psoriasis	5.77e-05	0.000214	CcSEcCtD
Sildenafil—Rash—Mycophenolic acid—psoriasis	5.75e-05	0.000213	CcSEcCtD
Sildenafil—Dermatitis—Mycophenolic acid—psoriasis	5.75e-05	0.000213	CcSEcCtD
Sildenafil—Pain—Prednisolone—psoriasis	5.74e-05	0.000213	CcSEcCtD
Sildenafil—Haemorrhage—Methotrexate—psoriasis	5.74e-05	0.000212	CcSEcCtD
Sildenafil—Urticaria—Mycophenolate mofetil—psoriasis	5.72e-05	0.000212	CcSEcCtD
Sildenafil—Headache—Mycophenolic acid—psoriasis	5.72e-05	0.000211	CcSEcCtD
Sildenafil—Decreased appetite—Hydrocortisone—psoriasis	5.7e-05	0.000211	CcSEcCtD
Sildenafil—Pharyngitis—Methotrexate—psoriasis	5.7e-05	0.000211	CcSEcCtD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.69e-05	0.00181	CbGpPWpGaD
Sildenafil—Body temperature increased—Mycophenolate mofetil—psoriasis	5.69e-05	0.000211	CcSEcCtD
Sildenafil—Abdominal pain—Mycophenolate mofetil—psoriasis	5.69e-05	0.000211	CcSEcCtD
Sildenafil—Urinary tract disorder—Methotrexate—psoriasis	5.67e-05	0.00021	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.66e-05	0.00021	CcSEcCtD
Sildenafil—Fatigue—Hydrocortisone—psoriasis	5.66e-05	0.000209	CcSEcCtD
Sildenafil—Vision blurred—Prednisone—psoriasis	5.64e-05	0.000209	CcSEcCtD
Sildenafil—Urethral disorder—Methotrexate—psoriasis	5.63e-05	0.000208	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.63e-05	0.000208	CcSEcCtD
Sildenafil—Pain—Hydrocortisone—psoriasis	5.61e-05	0.000208	CcSEcCtD
Sildenafil—Oedema—Betamethasone—psoriasis	5.61e-05	0.000207	CcSEcCtD
Sildenafil—Oedema—Dexamethasone—psoriasis	5.61e-05	0.000207	CcSEcCtD
Sildenafil—Insomnia—Triamcinolone—psoriasis	5.59e-05	0.000207	CcSEcCtD
Sildenafil—Infection—Betamethasone—psoriasis	5.57e-05	0.000206	CcSEcCtD
Sildenafil—Infection—Dexamethasone—psoriasis	5.57e-05	0.000206	CcSEcCtD
Sildenafil—Ill-defined disorder—Prednisone—psoriasis	5.55e-05	0.000205	CcSEcCtD
Sildenafil—Paraesthesia—Triamcinolone—psoriasis	5.55e-05	0.000205	CcSEcCtD
Sildenafil—Feeling abnormal—Prednisolone—psoriasis	5.54e-05	0.000205	CcSEcCtD
Sildenafil—Visual impairment—Methotrexate—psoriasis	5.53e-05	0.000205	CcSEcCtD
Sildenafil—Anaemia—Prednisone—psoriasis	5.53e-05	0.000205	CcSEcCtD
Sildenafil—Shock—Betamethasone—psoriasis	5.51e-05	0.000204	CcSEcCtD
Sildenafil—Shock—Dexamethasone—psoriasis	5.51e-05	0.000204	CcSEcCtD
Sildenafil—Dyspnoea—Triamcinolone—psoriasis	5.51e-05	0.000204	CcSEcCtD
Sildenafil—Nervous system disorder—Dexamethasone—psoriasis	5.5e-05	0.000203	CcSEcCtD
Sildenafil—Nervous system disorder—Betamethasone—psoriasis	5.5e-05	0.000203	CcSEcCtD
Sildenafil—Agitation—Prednisone—psoriasis	5.5e-05	0.000203	CcSEcCtD
Sildenafil—Tachycardia—Dexamethasone—psoriasis	5.47e-05	0.000202	CcSEcCtD
Sildenafil—Tachycardia—Betamethasone—psoriasis	5.47e-05	0.000202	CcSEcCtD
Sildenafil—Hypersensitivity—Cyclosporine—psoriasis	5.44e-05	0.000201	CcSEcCtD
Sildenafil—Dyspepsia—Triamcinolone—psoriasis	5.44e-05	0.000201	CcSEcCtD
Sildenafil—Erythema multiforme—Methotrexate—psoriasis	5.43e-05	0.000201	CcSEcCtD
Sildenafil—Nausea—Mycophenolic acid—psoriasis	5.42e-05	0.000201	CcSEcCtD
Sildenafil—Hyperhidrosis—Betamethasone—psoriasis	5.42e-05	0.0002	CcSEcCtD
Sildenafil—Hyperhidrosis—Dexamethasone—psoriasis	5.42e-05	0.0002	CcSEcCtD
Sildenafil—Feeling abnormal—Hydrocortisone—psoriasis	5.41e-05	0.0002	CcSEcCtD
Sildenafil—Malaise—Prednisone—psoriasis	5.39e-05	0.0002	CcSEcCtD
Sildenafil—ABCC4—Transmembrane transport of small molecules—CP—psoriasis	5.38e-05	0.00171	CbGpPWpGaD
Sildenafil—Vertigo—Prednisone—psoriasis	5.37e-05	0.000199	CcSEcCtD
Sildenafil—Eye disorder—Methotrexate—psoriasis	5.37e-05	0.000199	CcSEcCtD
Sildenafil—Gastrointestinal pain—Hydrocortisone—psoriasis	5.37e-05	0.000198	CcSEcCtD
Sildenafil—Syncope—Prednisone—psoriasis	5.36e-05	0.000198	CcSEcCtD
Sildenafil—Tinnitus—Methotrexate—psoriasis	5.35e-05	0.000198	CcSEcCtD
Sildenafil—Anorexia—Dexamethasone—psoriasis	5.34e-05	0.000198	CcSEcCtD
Sildenafil—Anorexia—Betamethasone—psoriasis	5.34e-05	0.000198	CcSEcCtD
Sildenafil—Urticaria—Prednisolone—psoriasis	5.34e-05	0.000197	CcSEcCtD
Sildenafil—Cardiac disorder—Methotrexate—psoriasis	5.33e-05	0.000197	CcSEcCtD
Sildenafil—Fatigue—Triamcinolone—psoriasis	5.33e-05	0.000197	CcSEcCtD
Sildenafil—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.31e-05	0.000196	CcSEcCtD
Sildenafil—Asthenia—Cyclosporine—psoriasis	5.3e-05	0.000196	CcSEcCtD
Sildenafil—Pain—Triamcinolone—psoriasis	5.28e-05	0.000195	CcSEcCtD
Sildenafil—Loss of consciousness—Prednisone—psoriasis	5.26e-05	0.000194	CcSEcCtD
Sildenafil—Hypotension—Dexamethasone—psoriasis	5.24e-05	0.000194	CcSEcCtD
Sildenafil—Hypotension—Betamethasone—psoriasis	5.24e-05	0.000194	CcSEcCtD
Sildenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.23e-05	0.00166	CbGpPWpGaD
Sildenafil—Pruritus—Cyclosporine—psoriasis	5.22e-05	0.000193	CcSEcCtD
Sildenafil—Urticaria—Hydrocortisone—psoriasis	5.21e-05	0.000193	CcSEcCtD
Sildenafil—Angiopathy—Methotrexate—psoriasis	5.21e-05	0.000193	CcSEcCtD
Sildenafil—ADORA2A—Signaling Pathways—HCAR2—psoriasis	5.19e-05	0.00165	CbGpPWpGaD
Sildenafil—Immune system disorder—Methotrexate—psoriasis	5.19e-05	0.000192	CcSEcCtD
Sildenafil—Abdominal pain—Hydrocortisone—psoriasis	5.19e-05	0.000192	CcSEcCtD
Sildenafil—Body temperature increased—Hydrocortisone—psoriasis	5.19e-05	0.000192	CcSEcCtD
Sildenafil—Convulsion—Prednisone—psoriasis	5.18e-05	0.000192	CcSEcCtD
Sildenafil—Mediastinal disorder—Methotrexate—psoriasis	5.18e-05	0.000191	CcSEcCtD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.17e-05	0.00164	CbGpPWpGaD
Sildenafil—Asthenia—Mycophenolate mofetil—psoriasis	5.17e-05	0.000191	CcSEcCtD
Sildenafil—Hypertension—Prednisone—psoriasis	5.16e-05	0.000191	CcSEcCtD
Sildenafil—Chills—Methotrexate—psoriasis	5.15e-05	0.000191	CcSEcCtD
Sildenafil—ABCC4—Transmembrane transport of small molecules—CARM1—psoriasis	5.13e-05	0.00163	CbGpPWpGaD
Sildenafil—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.11e-05	0.000189	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Betamethasone—psoriasis	5.11e-05	0.000189	CcSEcCtD
Sildenafil—Pruritus—Mycophenolate mofetil—psoriasis	5.1e-05	0.000189	CcSEcCtD
Sildenafil—Myalgia—Prednisone—psoriasis	5.09e-05	0.000188	CcSEcCtD
Sildenafil—Arthralgia—Prednisone—psoriasis	5.09e-05	0.000188	CcSEcCtD
Sildenafil—Feeling abnormal—Triamcinolone—psoriasis	5.09e-05	0.000188	CcSEcCtD
Sildenafil—Anxiety—Prednisone—psoriasis	5.07e-05	0.000188	CcSEcCtD
Sildenafil—Alopecia—Methotrexate—psoriasis	5.07e-05	0.000188	CcSEcCtD
Sildenafil—Insomnia—Dexamethasone—psoriasis	5.07e-05	0.000188	CcSEcCtD
Sildenafil—Insomnia—Betamethasone—psoriasis	5.07e-05	0.000188	CcSEcCtD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	5.06e-05	0.00161	CbGpPWpGaD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.06e-05	0.000187	CcSEcCtD
Sildenafil—Diarrhoea—Cyclosporine—psoriasis	5.05e-05	0.000187	CcSEcCtD
Sildenafil—Paraesthesia—Dexamethasone—psoriasis	5.03e-05	0.000186	CcSEcCtD
Sildenafil—Paraesthesia—Betamethasone—psoriasis	5.03e-05	0.000186	CcSEcCtD
Sildenafil—Discomfort—Prednisone—psoriasis	5.03e-05	0.000186	CcSEcCtD
Sildenafil—Mental disorder—Methotrexate—psoriasis	5.03e-05	0.000186	CcSEcCtD
Sildenafil—ADORA2A—GPCR downstream signaling—CCL20—psoriasis	5.02e-05	0.0016	CbGpPWpGaD
Sildenafil—Malnutrition—Methotrexate—psoriasis	5e-05	0.000185	CcSEcCtD
Sildenafil—Erythema—Methotrexate—psoriasis	5e-05	0.000185	CcSEcCtD
Sildenafil—Hypersensitivity—Prednisolone—psoriasis	4.95e-05	0.000183	CcSEcCtD
Sildenafil—Dyspepsia—Betamethasone—psoriasis	4.93e-05	0.000183	CcSEcCtD
Sildenafil—Dyspepsia—Dexamethasone—psoriasis	4.93e-05	0.000183	CcSEcCtD
Sildenafil—Diarrhoea—Mycophenolate mofetil—psoriasis	4.93e-05	0.000182	CcSEcCtD
Sildenafil—Urticaria—Triamcinolone—psoriasis	4.91e-05	0.000182	CcSEcCtD
Sildenafil—Body temperature increased—Triamcinolone—psoriasis	4.88e-05	0.000181	CcSEcCtD
Sildenafil—Dizziness—Cyclosporine—psoriasis	4.88e-05	0.000181	CcSEcCtD
Sildenafil—Oedema—Prednisone—psoriasis	4.88e-05	0.000181	CcSEcCtD
Sildenafil—Decreased appetite—Dexamethasone—psoriasis	4.87e-05	0.00018	CcSEcCtD
Sildenafil—Decreased appetite—Betamethasone—psoriasis	4.87e-05	0.00018	CcSEcCtD
Sildenafil—Infection—Prednisone—psoriasis	4.85e-05	0.000179	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Dexamethasone—psoriasis	4.84e-05	0.000179	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Betamethasone—psoriasis	4.84e-05	0.000179	CcSEcCtD
Sildenafil—Back pain—Methotrexate—psoriasis	4.84e-05	0.000179	CcSEcCtD
Sildenafil—Hypersensitivity—Hydrocortisone—psoriasis	4.83e-05	0.000179	CcSEcCtD
Sildenafil—Fatigue—Dexamethasone—psoriasis	4.83e-05	0.000179	CcSEcCtD
Sildenafil—Fatigue—Betamethasone—psoriasis	4.83e-05	0.000179	CcSEcCtD
Sildenafil—Shock—Prednisone—psoriasis	4.8e-05	0.000178	CcSEcCtD
Sildenafil—Pain—Dexamethasone—psoriasis	4.79e-05	0.000177	CcSEcCtD
Sildenafil—Pain—Betamethasone—psoriasis	4.79e-05	0.000177	CcSEcCtD
Sildenafil—Nervous system disorder—Prednisone—psoriasis	4.79e-05	0.000177	CcSEcCtD
Sildenafil—Tachycardia—Prednisone—psoriasis	4.76e-05	0.000176	CcSEcCtD
Sildenafil—Dizziness—Mycophenolate mofetil—psoriasis	4.76e-05	0.000176	CcSEcCtD
Sildenafil—ADORA2A—Signaling by NGF—NFKBIA—psoriasis	4.75e-05	0.00151	CbGpPWpGaD
Sildenafil—Skin disorder—Prednisone—psoriasis	4.74e-05	0.000175	CcSEcCtD
Sildenafil—Hyperhidrosis—Prednisone—psoriasis	4.72e-05	0.000175	CcSEcCtD
Sildenafil—Vision blurred—Methotrexate—psoriasis	4.71e-05	0.000174	CcSEcCtD
Sildenafil—Asthenia—Hydrocortisone—psoriasis	4.71e-05	0.000174	CcSEcCtD
Sildenafil—Vomiting—Cyclosporine—psoriasis	4.69e-05	0.000174	CcSEcCtD
Sildenafil—Rash—Cyclosporine—psoriasis	4.65e-05	0.000172	CcSEcCtD
Sildenafil—Anorexia—Prednisone—psoriasis	4.65e-05	0.000172	CcSEcCtD
Sildenafil—Dermatitis—Cyclosporine—psoriasis	4.65e-05	0.000172	CcSEcCtD
Sildenafil—Pruritus—Hydrocortisone—psoriasis	4.64e-05	0.000172	CcSEcCtD
Sildenafil—Ill-defined disorder—Methotrexate—psoriasis	4.64e-05	0.000172	CcSEcCtD
Sildenafil—Headache—Cyclosporine—psoriasis	4.62e-05	0.000171	CcSEcCtD
Sildenafil—Anaemia—Methotrexate—psoriasis	4.62e-05	0.000171	CcSEcCtD
Sildenafil—Feeling abnormal—Betamethasone—psoriasis	4.62e-05	0.000171	CcSEcCtD
Sildenafil—Feeling abnormal—Dexamethasone—psoriasis	4.62e-05	0.000171	CcSEcCtD
Sildenafil—Gastrointestinal pain—Betamethasone—psoriasis	4.58e-05	0.00017	CcSEcCtD
Sildenafil—Gastrointestinal pain—Dexamethasone—psoriasis	4.58e-05	0.00017	CcSEcCtD
Sildenafil—Vomiting—Mycophenolate mofetil—psoriasis	4.58e-05	0.000169	CcSEcCtD
Sildenafil—ADORA2A—Signaling by GPCR—CCL20—psoriasis	4.56e-05	0.00145	CbGpPWpGaD
Sildenafil—Hypersensitivity—Triamcinolone—psoriasis	4.55e-05	0.000168	CcSEcCtD
Sildenafil—Rash—Mycophenolate mofetil—psoriasis	4.54e-05	0.000168	CcSEcCtD
Sildenafil—Dermatitis—Mycophenolate mofetil—psoriasis	4.54e-05	0.000168	CcSEcCtD
Sildenafil—Headache—Mycophenolate mofetil—psoriasis	4.51e-05	0.000167	CcSEcCtD
Sildenafil—Malaise—Methotrexate—psoriasis	4.51e-05	0.000167	CcSEcCtD
Sildenafil—ADORA2A—Signaling Pathways—TAGAP—psoriasis	4.5e-05	0.00143	CbGpPWpGaD
Sildenafil—Vertigo—Methotrexate—psoriasis	4.49e-05	0.000166	CcSEcCtD
Sildenafil—Diarrhoea—Hydrocortisone—psoriasis	4.49e-05	0.000166	CcSEcCtD
Sildenafil—Leukopenia—Methotrexate—psoriasis	4.47e-05	0.000166	CcSEcCtD
Sildenafil—Urticaria—Dexamethasone—psoriasis	4.45e-05	0.000165	CcSEcCtD
Sildenafil—Urticaria—Betamethasone—psoriasis	4.45e-05	0.000165	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Prednisone—psoriasis	4.45e-05	0.000165	CcSEcCtD
Sildenafil—Dizziness—Prednisolone—psoriasis	4.44e-05	0.000164	CcSEcCtD
Sildenafil—Asthenia—Triamcinolone—psoriasis	4.43e-05	0.000164	CcSEcCtD
Sildenafil—Abdominal pain—Dexamethasone—psoriasis	4.43e-05	0.000164	CcSEcCtD
Sildenafil—Body temperature increased—Betamethasone—psoriasis	4.43e-05	0.000164	CcSEcCtD
Sildenafil—Abdominal pain—Betamethasone—psoriasis	4.43e-05	0.000164	CcSEcCtD
Sildenafil—Body temperature increased—Dexamethasone—psoriasis	4.43e-05	0.000164	CcSEcCtD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.43e-05	0.00141	CbGpPWpGaD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.43e-05	0.00141	CbGpPWpGaD
Sildenafil—Insomnia—Prednisone—psoriasis	4.42e-05	0.000163	CcSEcCtD
Sildenafil—Nausea—Cyclosporine—psoriasis	4.39e-05	0.000162	CcSEcCtD
Sildenafil—Paraesthesia—Prednisone—psoriasis	4.38e-05	0.000162	CcSEcCtD
Sildenafil—Pruritus—Triamcinolone—psoriasis	4.37e-05	0.000162	CcSEcCtD
Sildenafil—Cough—Methotrexate—psoriasis	4.36e-05	0.000161	CcSEcCtD
Sildenafil—Dizziness—Hydrocortisone—psoriasis	4.34e-05	0.000161	CcSEcCtD
Sildenafil—Convulsion—Methotrexate—psoriasis	4.33e-05	0.00016	CcSEcCtD
Sildenafil—Dyspepsia—Prednisone—psoriasis	4.3e-05	0.000159	CcSEcCtD
Sildenafil—Nausea—Mycophenolate mofetil—psoriasis	4.28e-05	0.000158	CcSEcCtD
Sildenafil—Chest pain—Methotrexate—psoriasis	4.26e-05	0.000157	CcSEcCtD
Sildenafil—Myalgia—Methotrexate—psoriasis	4.26e-05	0.000157	CcSEcCtD
Sildenafil—Arthralgia—Methotrexate—psoriasis	4.26e-05	0.000157	CcSEcCtD
Sildenafil—Decreased appetite—Prednisone—psoriasis	4.24e-05	0.000157	CcSEcCtD
Sildenafil—Rash—Prednisolone—psoriasis	4.24e-05	0.000157	CcSEcCtD
Sildenafil—Dermatitis—Prednisolone—psoriasis	4.23e-05	0.000157	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	4.23e-05	0.000156	CcSEcCtD
Sildenafil—Fatigue—Prednisone—psoriasis	4.21e-05	0.000156	CcSEcCtD
Sildenafil—Headache—Prednisolone—psoriasis	4.21e-05	0.000156	CcSEcCtD
Sildenafil—CYP3A7—Metabolism—NDUFA5—psoriasis	4.21e-05	0.00134	CbGpPWpGaD
Sildenafil—Discomfort—Methotrexate—psoriasis	4.2e-05	0.000156	CcSEcCtD
Sildenafil—ADORA2A—Circadian rythm related genes—JUN—psoriasis	4.18e-05	0.00133	CbGpPWpGaD
Sildenafil—Constipation—Prednisone—psoriasis	4.17e-05	0.000154	CcSEcCtD
Sildenafil—Vomiting—Hydrocortisone—psoriasis	4.17e-05	0.000154	CcSEcCtD
Sildenafil—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	4.15e-05	0.00132	CbGpPWpGaD
Sildenafil—Rash—Hydrocortisone—psoriasis	4.14e-05	0.000153	CcSEcCtD
Sildenafil—Dermatitis—Hydrocortisone—psoriasis	4.13e-05	0.000153	CcSEcCtD
Sildenafil—Headache—Hydrocortisone—psoriasis	4.11e-05	0.000152	CcSEcCtD
Sildenafil—Dizziness—Triamcinolone—psoriasis	4.09e-05	0.000151	CcSEcCtD
Sildenafil—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	4.06e-05	0.00129	CbGpPWpGaD
Sildenafil—Infection—Methotrexate—psoriasis	4.05e-05	0.00015	CcSEcCtD
Sildenafil—Feeling abnormal—Prednisone—psoriasis	4.02e-05	0.000149	CcSEcCtD
Sildenafil—Asthenia—Betamethasone—psoriasis	4.02e-05	0.000149	CcSEcCtD
Sildenafil—Asthenia—Dexamethasone—psoriasis	4.02e-05	0.000149	CcSEcCtD
Sildenafil—Nervous system disorder—Methotrexate—psoriasis	4e-05	0.000148	CcSEcCtD
Sildenafil—Gastrointestinal pain—Prednisone—psoriasis	3.99e-05	0.000148	CcSEcCtD
Sildenafil—Nausea—Prednisolone—psoriasis	3.99e-05	0.000148	CcSEcCtD
Sildenafil—PDE5A—Hemostasis—VEGFA—psoriasis	3.98e-05	0.00126	CbGpPWpGaD
Sildenafil—Pruritus—Dexamethasone—psoriasis	3.97e-05	0.000147	CcSEcCtD
Sildenafil—Pruritus—Betamethasone—psoriasis	3.97e-05	0.000147	CcSEcCtD
Sildenafil—Skin disorder—Methotrexate—psoriasis	3.96e-05	0.000147	CcSEcCtD
Sildenafil—Hyperhidrosis—Methotrexate—psoriasis	3.94e-05	0.000146	CcSEcCtD
Sildenafil—Vomiting—Triamcinolone—psoriasis	3.93e-05	0.000145	CcSEcCtD
Sildenafil—PDE6G—Disease—HLA-A—psoriasis	3.92e-05	0.00125	CbGpPWpGaD
Sildenafil—Nausea—Hydrocortisone—psoriasis	3.9e-05	0.000144	CcSEcCtD
Sildenafil—Rash—Triamcinolone—psoriasis	3.9e-05	0.000144	CcSEcCtD
Sildenafil—ADORA2A—Signaling by NGF—TYK2—psoriasis	3.89e-05	0.00124	CbGpPWpGaD
Sildenafil—Dermatitis—Triamcinolone—psoriasis	3.89e-05	0.000144	CcSEcCtD
Sildenafil—Anorexia—Methotrexate—psoriasis	3.89e-05	0.000144	CcSEcCtD
Sildenafil—Urticaria—Prednisone—psoriasis	3.88e-05	0.000143	CcSEcCtD
Sildenafil—Headache—Triamcinolone—psoriasis	3.87e-05	0.000143	CcSEcCtD
Sildenafil—Abdominal pain—Prednisone—psoriasis	3.86e-05	0.000143	CcSEcCtD
Sildenafil—Body temperature increased—Prednisone—psoriasis	3.86e-05	0.000143	CcSEcCtD
Sildenafil—Diarrhoea—Betamethasone—psoriasis	3.84e-05	0.000142	CcSEcCtD
Sildenafil—Diarrhoea—Dexamethasone—psoriasis	3.84e-05	0.000142	CcSEcCtD
Sildenafil—Hypotension—Methotrexate—psoriasis	3.81e-05	0.000141	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Methotrexate—psoriasis	3.72e-05	0.000138	CcSEcCtD
Sildenafil—Dizziness—Betamethasone—psoriasis	3.71e-05	0.000137	CcSEcCtD
Sildenafil—Dizziness—Dexamethasone—psoriasis	3.71e-05	0.000137	CcSEcCtD
Sildenafil—Insomnia—Methotrexate—psoriasis	3.69e-05	0.000137	CcSEcCtD
Sildenafil—Nausea—Triamcinolone—psoriasis	3.67e-05	0.000136	CcSEcCtD
Sildenafil—PDE6G—Disease—APOE—psoriasis	3.66e-05	0.00116	CbGpPWpGaD
Sildenafil—Paraesthesia—Methotrexate—psoriasis	3.66e-05	0.000136	CcSEcCtD
Sildenafil—Dyspnoea—Methotrexate—psoriasis	3.64e-05	0.000135	CcSEcCtD
Sildenafil—Somnolence—Methotrexate—psoriasis	3.63e-05	0.000134	CcSEcCtD
Sildenafil—Hypersensitivity—Prednisone—psoriasis	3.6e-05	0.000133	CcSEcCtD
Sildenafil—Dyspepsia—Methotrexate—psoriasis	3.59e-05	0.000133	CcSEcCtD
Sildenafil—CYP3A7—Metabolism—CYP2S1—psoriasis	3.58e-05	0.00114	CbGpPWpGaD
Sildenafil—Vomiting—Dexamethasone—psoriasis	3.56e-05	0.000132	CcSEcCtD
Sildenafil—Vomiting—Betamethasone—psoriasis	3.56e-05	0.000132	CcSEcCtD
Sildenafil—Decreased appetite—Methotrexate—psoriasis	3.55e-05	0.000131	CcSEcCtD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	3.54e-05	0.00113	CbGpPWpGaD
Sildenafil—Rash—Dexamethasone—psoriasis	3.53e-05	0.000131	CcSEcCtD
Sildenafil—Rash—Betamethasone—psoriasis	3.53e-05	0.000131	CcSEcCtD
Sildenafil—Dermatitis—Dexamethasone—psoriasis	3.53e-05	0.000131	CcSEcCtD
Sildenafil—Dermatitis—Betamethasone—psoriasis	3.53e-05	0.000131	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Methotrexate—psoriasis	3.52e-05	0.00013	CcSEcCtD
Sildenafil—Fatigue—Methotrexate—psoriasis	3.52e-05	0.00013	CcSEcCtD
Sildenafil—Headache—Dexamethasone—psoriasis	3.51e-05	0.00013	CcSEcCtD
Sildenafil—Headache—Betamethasone—psoriasis	3.51e-05	0.00013	CcSEcCtD
Sildenafil—Asthenia—Prednisone—psoriasis	3.5e-05	0.00013	CcSEcCtD
Sildenafil—Pain—Methotrexate—psoriasis	3.49e-05	0.000129	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—SOCS1—psoriasis	3.48e-05	0.0011	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—CARM1—psoriasis	3.47e-05	0.0011	CbGpPWpGaD
Sildenafil—Pruritus—Prednisone—psoriasis	3.45e-05	0.000128	CcSEcCtD
Sildenafil—PDE6G—Disease—NOS2—psoriasis	3.41e-05	0.00108	CbGpPWpGaD
Sildenafil—Feeling abnormal—Methotrexate—psoriasis	3.36e-05	0.000124	CcSEcCtD
Sildenafil—Diarrhoea—Prednisone—psoriasis	3.34e-05	0.000124	CcSEcCtD
Sildenafil—Gastrointestinal pain—Methotrexate—psoriasis	3.34e-05	0.000123	CcSEcCtD
Sildenafil—Nausea—Betamethasone—psoriasis	3.33e-05	0.000123	CcSEcCtD
Sildenafil—Nausea—Dexamethasone—psoriasis	3.33e-05	0.000123	CcSEcCtD
Sildenafil—Urticaria—Methotrexate—psoriasis	3.24e-05	0.00012	CcSEcCtD
Sildenafil—Dizziness—Prednisone—psoriasis	3.23e-05	0.000119	CcSEcCtD
Sildenafil—Abdominal pain—Methotrexate—psoriasis	3.23e-05	0.000119	CcSEcCtD
Sildenafil—Body temperature increased—Methotrexate—psoriasis	3.23e-05	0.000119	CcSEcCtD
Sildenafil—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.15e-05	0.001	CbGpPWpGaD
Sildenafil—Vomiting—Prednisone—psoriasis	3.1e-05	0.000115	CcSEcCtD
Sildenafil—Rash—Prednisone—psoriasis	3.08e-05	0.000114	CcSEcCtD
Sildenafil—Dermatitis—Prednisone—psoriasis	3.08e-05	0.000114	CcSEcCtD
Sildenafil—Headache—Prednisone—psoriasis	3.06e-05	0.000113	CcSEcCtD
Sildenafil—CYP2E1—Metabolism—NDUFA5—psoriasis	3.05e-05	0.000968	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—NDUFA5—psoriasis	3.04e-05	0.000966	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—NFKB1—psoriasis	3.03e-05	0.000963	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—TP53—psoriasis	3.01e-05	0.000955	CbGpPWpGaD
Sildenafil—Hypersensitivity—Methotrexate—psoriasis	3.01e-05	0.000111	CcSEcCtD
Sildenafil—ABCC4—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.97e-05	0.000942	CbGpPWpGaD
Sildenafil—Asthenia—Methotrexate—psoriasis	2.93e-05	0.000108	CcSEcCtD
Sildenafil—Nausea—Prednisone—psoriasis	2.9e-05	0.000107	CcSEcCtD
Sildenafil—Pruritus—Methotrexate—psoriasis	2.89e-05	0.000107	CcSEcCtD
Sildenafil—CYP1A1—Metabolism—NDUFA5—psoriasis	2.87e-05	0.000912	CbGpPWpGaD
Sildenafil—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	2.8e-05	0.000889	CbGpPWpGaD
Sildenafil—PDE6G—Disease—TYK2—psoriasis	2.8e-05	0.000888	CbGpPWpGaD
Sildenafil—Diarrhoea—Methotrexate—psoriasis	2.79e-05	0.000103	CcSEcCtD
Sildenafil—ADORA2A—Circadian rythm related genes—TP53—psoriasis	2.76e-05	0.000876	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—STAT3—psoriasis	2.73e-05	0.000865	CbGpPWpGaD
Sildenafil—Dizziness—Methotrexate—psoriasis	2.7e-05	9.98e-05	CcSEcCtD
Sildenafil—ADORA2A—Signaling Pathways—CCL20—psoriasis	2.7e-05	0.000856	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.68e-05	0.000851	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—NOS2—psoriasis	2.64e-05	0.000838	CbGpPWpGaD
Sildenafil—Vomiting—Methotrexate—psoriasis	2.59e-05	9.6e-05	CcSEcCtD
Sildenafil—CYP2E1—Metabolism—CYP2S1—psoriasis	2.59e-05	0.000823	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—CYP2S1—psoriasis	2.59e-05	0.000821	CbGpPWpGaD
Sildenafil—Rash—Methotrexate—psoriasis	2.57e-05	9.52e-05	CcSEcCtD
Sildenafil—Dermatitis—Methotrexate—psoriasis	2.57e-05	9.51e-05	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—LEP—psoriasis	2.57e-05	0.000815	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—APOE—psoriasis	2.57e-05	0.000815	CbGpPWpGaD
Sildenafil—Headache—Methotrexate—psoriasis	2.56e-05	9.46e-05	CcSEcCtD
Sildenafil—PDE6G—Disease—CD4—psoriasis	2.53e-05	0.000803	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—IL6—psoriasis	2.52e-05	0.000802	CbGpPWpGaD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	2.48e-05	0.000786	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—CYP2S1—psoriasis	2.44e-05	0.000776	CbGpPWpGaD
Sildenafil—Nausea—Methotrexate—psoriasis	2.42e-05	8.97e-05	CcSEcCtD
Sildenafil—ADORA2A—GPCR ligand binding—CXCL8—psoriasis	2.4e-05	0.000762	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—NFKBIA—psoriasis	2.39e-05	0.000759	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—NDUFA5—psoriasis	2.35e-05	0.000747	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.19e-05	0.000696	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NDUFA5—psoriasis	2.16e-05	0.000687	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NDUFA5—psoriasis	2.14e-05	0.000681	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—CAT—psoriasis	2.13e-05	0.000677	CbGpPWpGaD
Sildenafil—ABCC5—Disease—HLA-A—psoriasis	2.12e-05	0.000673	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—CYP2S1—psoriasis	2e-05	0.000635	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2e-05	0.000635	CbGpPWpGaD
Sildenafil—ABCC5—Disease—APOE—psoriasis	1.98e-05	0.000628	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—TYK2—psoriasis	1.96e-05	0.000622	CbGpPWpGaD
Sildenafil—PDE6G—Disease—STAT3—psoriasis	1.96e-05	0.000622	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—IL6—psoriasis	1.9e-05	0.000605	CbGpPWpGaD
Sildenafil—ABCC5—Disease—NOS2—psoriasis	1.84e-05	0.000586	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—CYP2S1—psoriasis	1.84e-05	0.000584	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—CYP2S1—psoriasis	1.82e-05	0.000579	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—CARM1—psoriasis	1.75e-05	0.000555	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—CXCL8—psoriasis	1.71e-05	0.000541	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—APOE—psoriasis	1.66e-05	0.000526	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—JUN—psoriasis	1.59e-05	0.000503	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—VEGFA—psoriasis	1.53e-05	0.000486	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—NFKB1—psoriasis	1.53e-05	0.000485	CbGpPWpGaD
Sildenafil—ABCC5—Disease—TYK2—psoriasis	1.51e-05	0.00048	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—SOCS1—psoriasis	1.48e-05	0.000471	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—PPARG—psoriasis	1.44e-05	0.000458	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—TYK2—psoriasis	1.42e-05	0.000449	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NDUFA5—psoriasis	1.41e-05	0.000449	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—VEGFA—psoriasis	1.38e-05	0.00044	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—STAT3—psoriasis	1.37e-05	0.000435	CbGpPWpGaD
Sildenafil—PDE6G—Disease—IL6—psoriasis	1.37e-05	0.000434	CbGpPWpGaD
Sildenafil—ABCC5—Disease—CD4—psoriasis	1.37e-05	0.000434	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—CXCL8—psoriasis	1.36e-05	0.000431	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.28e-05	0.000407	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—CARM1—psoriasis	1.27e-05	0.000402	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—CARM1—psoriasis	1.26e-05	0.000401	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—CXCL8—psoriasis	1.23e-05	0.000391	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CYP2S1—psoriasis	1.2e-05	0.000382	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—CARM1—psoriasis	1.19e-05	0.000379	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—TP53—psoriasis	1.16e-05	0.000367	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.12e-05	0.000354	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—LEP—psoriasis	1.1e-05	0.000348	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—APOE—psoriasis	1.1e-05	0.000348	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—CAT—psoriasis	1.07e-05	0.000341	CbGpPWpGaD
Sildenafil—ABCC5—Disease—STAT3—psoriasis	1.06e-05	0.000336	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.05e-05	0.000333	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—TP53—psoriasis	1.05e-05	0.000332	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—NFKBIA—psoriasis	1.02e-05	0.000324	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—CARM1—psoriasis	9.76e-06	0.00031	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—IL6—psoriasis	9.58e-06	0.000304	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.55e-06	0.000303	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.13e-06	0.00029	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—CARM1—psoriasis	8.98e-06	0.000285	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—CARM1—psoriasis	8.9e-06	0.000283	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—TYK2—psoriasis	8.36e-06	0.000265	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—APOE—psoriasis	8.35e-06	0.000265	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.32e-06	0.000264	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—CAT—psoriasis	7.78e-06	0.000247	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—CAT—psoriasis	7.77e-06	0.000247	CbGpPWpGaD
Sildenafil—ABCC5—Disease—IL6—psoriasis	7.39e-06	0.000235	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—CAT—psoriasis	7.34e-06	0.000233	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CXCL8—psoriasis	7.28e-06	0.000231	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PPARG—psoriasis	7.27e-06	0.000231	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—IL6—psoriasis	6.92e-06	0.00022	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—JUN—psoriasis	6.77e-06	0.000215	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—NFKB1—psoriasis	6.51e-06	0.000207	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—APOE—psoriasis	6.05e-06	0.000192	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—APOE—psoriasis	6.04e-06	0.000192	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—CAT—psoriasis	6e-06	0.000191	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—VEGFA—psoriasis	5.91e-06	0.000188	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CARM1—psoriasis	5.87e-06	0.000186	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—STAT3—psoriasis	5.85e-06	0.000186	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—APOE—psoriasis	5.7e-06	0.000181	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—CAT—psoriasis	5.52e-06	0.000175	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—CAT—psoriasis	5.48e-06	0.000174	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PPARG—psoriasis	5.27e-06	0.000167	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PPARG—psoriasis	5.26e-06	0.000167	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PPARG—psoriasis	4.97e-06	0.000158	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—APOE—psoriasis	4.67e-06	0.000148	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—TP53—psoriasis	4.47e-06	0.000142	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—APOE—psoriasis	4.29e-06	0.000136	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—APOE—psoriasis	4.25e-06	0.000135	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—IL6—psoriasis	4.09e-06	0.00013	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PPARG—psoriasis	4.06e-06	0.000129	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PPARG—psoriasis	3.74e-06	0.000119	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PPARG—psoriasis	3.71e-06	0.000118	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CAT—psoriasis	3.61e-06	0.000115	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—APOE—psoriasis	2.81e-06	8.91e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PPARG—psoriasis	2.44e-06	7.76e-05	CbGpPWpGaD
